|Bid||242.00 x 243000|
|Ask||240.00 x 260500|
|Day's Range||238.40 - 242.10|
|52 Week Range||223.70 - 273.00|
|PE Ratio (TTM)||21.35|
|Earnings Date||Feb 1, 2018|
|Forward Dividend & Yield||8.22 (3.22%)|
|1y Target Est||273.71|
The question for patients with early-stage HER2+ breast cancer is if it’s worth taking a treatment (Nerlynx) that lowers the risk of distant recurrence by less than 2% at 5 years, and which has not yet been studied over the long term.
It’s safer to invest in, cheap and offers a huge potential in continued earnings recovery. As the big investment banks start to look ahead to 2018, UBS has already picked one of its favorites and the needle ...
Drugmakers plunged off a patent cliff earlier this decade, losing billions in sales as lucrative branded drugs lost exclusivity. An expensive lobbying effort aimed at preventing a repeat is paying off....
Roche Holding AG led European stocks lower after the Swiss pharmaceutical company unveiled data on the Aphinity breast-cancer study that disappointed analysts.
Roche’s breast cancer Perjeta decreased the risk of cancer returning in women whose tumors could be entirely removed using surgery, but the results were less impressive than what doctors hoped for--or what investors expected.
Roche Holding AG’s new breast cancer combination therapy barely outperformed a current gold-standard drug for the disease -- the company’s own decades-old Herceptin -- in its latest study.
Roche Holding AG is seeking a partner with experimental drugs that might help repair the damage caused to the nervous system by multiple sclerosis -- considered a key step in managing the debilitating ...